ClinicalTrials.gg
CompletedNCT04083833Updated Sep 10, 2019

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

A Phase 1 interventional study of Tetrodotoxin and Placebos in TQT Study, sponsored by Wex Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by Wex Pharmaceuticals Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 7 months ago, and no results have been posted to the registry.
  • Registered 1 year 6 months after the study started (first participant enrolled Feb 2018, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To determine if a single subcutaneous (SC) administration of TTX at various dose levels has an effect on the QT/QTc intervals when assessing concentration QT (C-QT) relationship (i.e., QT/QTc intervals prolongation in relation to plasma levels of TTX) in healthy adult subjects.

Secondary:

  1. To determine if a single SC administration of TTX at various dose levels has an effect on other important electrocardiogram (ECG) parameters in healthy adult subjects.
  2. To demonstrate sensitivity of this QTc assay using moxifloxacin as a positive control.
  3. To confirm plasma pharmacokinetic (PK) of a single SC administration of TTX at various dose levels when administered to healthy adult subjects.
  4. To determine the overall safety and tolerability of a single SC administration of TTX at various dose levels when administered to healthy adult subjects.

Test Product, Dose, Duration, Mode of Administration, and Batch Number:

The test product was 30 µg/mL tetrodotoxin (TTX) for injection, Lot No. F141124-001.

Subjects were also administered:

  • Tetrodotoxin matching placebo a sterile 0.9% sodium chloride injection or normal saline for injection, Lot No. 84-093-DK
  • 400 mg Avelox® (moxifloxacin hydrochloride) tablets, Lot No. BXHJ1S1
  • Moxifloxacin matching placebo film-coated tablets, Id.-No.: K15372, Batch No.: C1606007

Treatments were as follows:

Treatment Arm (n = 9)

Treatment A:

(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)

Treatment B:

(Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)

Treatment C:

(Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)

Subjects randomized to the Control Arm were further randomized to receive 1 of 2 treatment sequences (Treatment Sequence DEF [n = 8] and Treatment Sequence GHI [n = 8]):

Control Arm (n = 16)

Treatment D:

(Period 1) A single matching-TTX placebo (0.5 mL of placebo injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)

Treatment E:

(Period 2) A single matching-TTX placebo (1 mL of placebo injection solution) administered as 1 SC injection with a single oral 400 mg moxifloxacin (1 x 400 mg tablet)

Treatment F:

(Period 3) A single matching-TTX placebo (1.5 mL of placebo injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)

Treatment G:

(Period 1) A single matching-TTX placebo (0.5 mL of placebo injection solution) administered as 1 SC injection with a single oral 400 mg moxifloxacin (1 x 400 mg tablet)

Treatment H:

(Period 2) A single matching-TTX placebo (1 mL of placebo injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)

Treatment I:

(Period 3) A single matching-TTX placebo (1.5 mL of placebo injection solution) administered as 2 SC injections with a single oral 400 mg moxifloxacin (1 x 400 mg tablet) All oral study drugs were administered with approximately 240 mL of water.

02

Conditions studied

  • TQT Study

Keywords

  • TQT TTX Halneuron cardiac safety
03

In context

Lead sponsor

Wex Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, male or female 18 55 years of age, inclusive, at screening.
  2. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to the first dose and throughout the study.
  3. (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
  4. Medically healthy with no medical history, physical examination, neurologic examinations, laboratory profiles, vital signs, or ECGs, as deemed by the PI or designee.
  5. For a female of : either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using one of the following acceptable methods:

    • non-hormone releasing intrauterine device for at least 3 months prior to the first dose and throughout the study.
    • surgical sterilization of the partner (vasectomy for 4 months minimum prior to the first dose).
    • physical barrier method (e.g., condom, diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study.

    A female subject who claims to be sexually inactive, but becomes sexually active during the course of the study must agree to use a physical barrier method (e.g., condom, diaphragm) with spermicide from the time of the start of sexual activity and throughout the study.

    In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 28 days following the last dose.

  6. For a female of non childbearing potential: must have undergone one of the following sterilization procedures at least 6 months prior to the first dose:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy; or be with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  7. A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to first dose of study drug. A male who has been vasectomized less than 4 months prior to study first dose must follow the same restrictions as a non vasectomized male).
  8. If male, must agree not to donate sperm from the first dose until 90 days after last dosing.
  9. No clinically significant history or presence of findings as judged by the PI at screening and check-in of Period 1, including each criterion as listed below:

    • Normal sinus rhythm (heart rate between 50 bpm and 100 bpm inclusive);
    • interval ≤ 450 msec;
    • QRS interval ≤ 110 msec; if > 110 msec, result will be confirmed by a manual over read;
    • PR interval ≤ 220 msec.
  10. Normal renal function ( from 80 to 180 mL/minute per Cockcroft-Gault equation; 24-hour urinary creatinine collection may be used for borderline cases).
  11. PEF of ≥ 80% per handheld meter and oxygen saturation of ≥ 95% by pulse oximetry.
  12. Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose.
  5. History or presence of:

    • risk factors for Torsade de Pointes (e.g., heart failure, cardiomyopathy, or family history of Long Syndrome);
    • sick sinus syndrome, second or third degree atrioventricular block, myocardial infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities.
  6. Any acute or chronic pain conditions requiring ongoing treatment or limiting daily activities.
  7. History of fainting upon blood sampling or needle puncture.
  8. Findings during the screening neurological examination that could interfere with or preclude neurological assessments during the study, in the opinion of the PI or designee.
  9. History or presence of neurologic or neuromuscular disease.
  10. Allergy to band aids, adhesive dressing or medical tape.
  11. History or presence of or idiosyncratic reaction to the study drug(s), related compounds, or fish.
  12. History of anaphylaxis to a medication, dietary item, or environment exposures (including bee stings).
  13. Female subjects with a positive pregnancy test or lactating.
  14. Positive urine drug, cotinine, or alcohol results at screening or check in of Period 1.
  15. Positive results at screening for (HIV), surface antigen (HBsAg) or virus (HCV).
  16. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  17. Seated heart rate is lower than 50 bpm or higher than 99 bpm at screening.
  18. Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dose and throughout the study.
  19. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 30 days prior to the first dose and throughout the study.
  20. Donation of blood or significant blood loss within 56 days prior to the first dose.
  21. Plasma donation within 7 days prior to the first dose.
  22. Participation in another clinical study within 30 days prior to the first dose. The 30 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    (Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)

    Drug: Tetrodotoxin

  • Placebo comparator
    Control

    Treatment D: (Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo Treatment E: (Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin Treatment F: (Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo Treatment G: (Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin Treatment H: (Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo Treatment I: (Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin

    Drug: Placebos

Interventions

  • A single TTX dose in a dose ascending study

    Also known as: Halneuron

  • DrugPlacebos

    matching placebo comparator

06

What researchers measure

Primary outcomes

  1. Cardiodynamic

    The primary cardiodynamic endpoint was the effect of TTX plasma concentrations on the QTc interval using linear mixed-effect exposure-response modeling, including the predicted ddQTc at Cmax values corresponding to exposure levels of interest.

    Time frame: 24 hours

Secondary outcomes

  1. ECG Paramenters

    Other ECG parameters such as QTc, QT, PR, and RR intervals, QRS duration, and HR

    Time frame: 24 hours

  2. ECG Paramenters

    Abnormalities in T wave morphology and pathologic U waves will be reported when identified by the cardiologist reviewer, as appropriate.

    Time frame: 24 hours

  3. Assay Sensitivity

    3. Assay sensitivity assessment with ddQTc at the geometric mean Cmax value predicted from a linear mixed-effect model evaluating the relationship between QTc and moxifloxacin plasma concentrations (exposure-response modeling).

    Time frame: 24 hours

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Mar 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2019
First posted
Sep 10, 2019
StartActual
Feb 7, 2018
Primary completionActual
Mar 24, 2018
CompletionActual
Mar 24, 2018
Last update
Sep 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04083833
Lead sponsor
Wex Pharmaceuticals Inc.
Collaborators
Celerion
Responsible party
Sponsor
First posted
Sep 10, 2019
Start date
Feb 7, 2018
Primary completion
Mar 24, 2018
Completion
Mar 24, 2018
Last update
Sep 10, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tetrodotoxin

Start the discussion